Back to top
more

Aethlon Medical (AEMD)

(Delayed Data from NSDQ)

$1.36 USD

1.36
19,761

-0.14 (-9.51%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $1.33 -0.03 (-2.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (167 out of 252)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Company Summary

Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.

General Information

Aethlon Medical, Inc

11555 SORRENTO VALLEY ROAD SUITE 203

SAN DIEGO, CA 92121

Phone: 619-941-0360

Fax: NA

Web: http://www.aethlonmedical.com

Email: susan@sanoonan.com

Industry Medical - HMOs
Sector Medical
Fiscal Year End March
Last Reported Quarter 3/31/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 6/26/2024

EPS Information

Current Quarter EPS Consensus Estimate -1.18
Current Year EPS Consensus Estimate -4.98
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 6/26/2024

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 1.50
52 Week High 5.00
52 Week Low 1.35
Beta 1.88
20 Day Moving Average 7,263.10
Target Price Consensus 31.55

AEMD

% Price Change
4 Week -10.54
12 Week -16.50
YTD -31.37
% Price Change Relative to S&P 500
4 Week -6.89
12 Week -18.85
YTD -35.16
Share Information
Shares Outstanding (millions) 2.62
Market Capitalization (millions) 3.94
Short Ratio NA
Last Split Date 10/15/2019
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year -14.17%
vs. Previous Quarter -12.30%
   
Sales Growth
vs. Previous Year 4,315.38%
vs. Previous Quarter NA%
   
Price Ratios
Price/Book 0.49
Price/Cash Flow NA
Price / Sales NA
ROE
3/31/24 NA
12/31/23 -106.28
9/30/23 -83.43
ROA
3/31/24 NA
12/31/23 -86.60
9/30/23 -69.59
Current Ratio
3/31/24 NA
12/31/23 3.93
9/30/23 6.13
Quick Ratio
3/31/24 NA
12/31/23 3.93
9/30/23 6.13
Operating Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Net Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Pre-Tax Margin
3/31/24 NA
12/31/23 -2,133.97
9/30/23 -2,026.66
Book Value
3/31/24 NA
12/31/23 3.05
9/30/23 4.16
Inventory Turnover
3/31/24 NA
12/31/23 NA
9/30/23 NA
Debt-to-Equity
3/31/24 NA
12/31/23 0.00
9/30/23 0.00
Debt to Capital
3/31/24 NA
12/31/23 0.00
9/30/23 0.00